CSPIA
PDSB icon

Cary Street Partners Investment Advisory’s PDS Biotechnology PDSB Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,131
Closed -$31K – 1466
2023
Q3 		$31K Buy
6,131
+4,000
+188% +$21.9K ﹤0.01% 986
2023
Q2 		$10.7K Hold
2,131
– – ﹤0.01% 1226
2023
Q1 		$13.1K Hold
2,131
– – ﹤0.01% 1074
2022
Q4 		$28.1K Buy
+2,131
New +$15K ﹤0.01% 874

Other funds holding PDSB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cary Street Partners Investment Advisory's PDSB Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of PDS Biotechnology (PDSB) in Q4 2023, closing a stake of 6,131 shares — an estimated $31K sold.

Cary Street Partners Investment Advisory first reported a position in PDSB in Q4 2022 and held it in 4 quarters. The position peaked at $31K in Q3 2023. 77 funds tracked by Wall St. Rank hold PDSB as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining PDS Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 6,131 PDS Biotechnology shares in Q4 2023, an estimated $31K.
  • Cary Street Partners Investment Advisory first reported a position in PDS Biotechnology in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's PDS Biotechnology position peaked at $31K in Q3 2023.
  • 77 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.